Sedation in ICU Settings

Introduction to Sedative Medications

• The American College of Critical Care Medicine recommends propofol and dexmedetomidine as first-line sedative medications in the ICU setting due to their improved patient outcomes, including shorter duration of mechanical ventilation, reduced delirium incidence, and better patient communication 1, 2

ICU Sedative Medications

• Propofol has a rapid onset and short elimination half-life, making it suitable for daily sedation interruption and neurological assessments, with dosing at 5-50 μg/kg/min maintenance infusion 3, 4
• Dexmedetomidine has an onset of 5-10 minutes and a half-life of 1.8-3.1 hours, with dosing at 0.2-0.7 μg/kg/hr, and is associated with improved patient communication and reduced delirium compared to benzodiazepines 1, 3
• Midazolam is a second-line option with a quick onset and intermediate half-life, but is associated with increased delirium risk and longer mechanical ventilation 1, 2, 3

Sedation Management

• Target light sedation, rather than deep sedation, to minimize negative consequences in ICU patients 3, 4
• Non-pharmacological approaches, such as adequate analgesia and reorientation, should be attempted before administering sedatives 3
• Benzodiazepine use is a strong independent risk factor for developing delirium 1, 2
• Daily sedation interruption should be considered to assess neurologic status and reduce total sedative exposure 4

Sedative Selection and Monitoring

• Use validated sedation scales to titrate sedation to target 3
• Implement sedation protocols designed to minimize sedative use 3
• Monitor for propofol infusion syndrome with high-dose or prolonged infusions 4

Sedation Management in ICU Patients with Dementia and Delirium

Introduction to Sedation Management

• The Society of Critical Care Medicine recommends that in adult ICU patients with delirium unrelated to alcohol or benzodiazepine withdrawal, continuous IV infusions of dexmedetomidine rather than benzodiazepine infusions be administered for sedation to reduce the duration of delirium (Grade 2B recommendation) 5, 6

Risks of Benzodiazepines

• Benzodiazepine use is a strong independent risk factor for developing delirium in ICU patients 7, 8, 6
• Pre-existing dementia is one of four baseline risk factors positively and significantly associated with developing delirium in the ICU 8, 6

Preferred Sedatives

• Dexmedetomidine reduces delirium duration by approximately 20% compared to benzodiazepines (midazolam or lorazepam) 9, 10, 5
• Dexmedetomidine reduced time to liberation from mechanical ventilation (3.7 days) compared to midazolam (5.6 days) 9, 10

Guideline-Based Recommendations

• Non-benzodiazepine sedatives (propofol or dexmedetomidine) are preferred over benzodiazepines for ICU sedation 7
• Light sedation levels should be maintained rather than deep sedation to minimize negative consequences 11, 12, 13, 8

Monitoring and Management

• Use validated delirium screening tools (CAM-ICU or ICDSC) daily 7, 8
• Use validated sedation scales (RASS or SAS) to titrate to light sedation targets 7, 8
• Implement daily sedation interruption or light sedation protocols 7, 6